Aarti Drugs

Price chart

Previous close

₹449.90

Open

₹450.80

Day high

₹513.00

Day low

₹446.75

Listed on NSE since 19 September 2003.

Market value

₹4,580.84 Cr

P/E (trailing)

24.15

EPS (trailing)

₹20.78

Price to book

2.72

Dividend yield

0.44%

Return on equity

14.5%

Debt to equity

0.37

Profit margin

8.0%

Beta

0.26

Volume today

1.18 Cr

Average volume

4.60 L

Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.

Source: Yahoo Finance, from annual reports. Consolidated where reported.

Quarterly results are unavailable from NSE right now, or none are on file for this company.

The balance sheet is unavailable from NSE right now, or none is on file for this company.

Aarti Drugs Limited, through its subsidiaries, engages in the manufacture and marketing of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, norfloxacin, ofloxacin, metronidazole, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzenesulphonyl chloride, benzenesulphonic acid, methyl benzenesulfonate, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for antifungal, cardiovascular, and antidiabetic therapeutic areas, as well as non-steroidal anti-inflammatory drugs. The company was incorporated in 1984 and is headquartered in Mumbai, India.

Industry

Drug Manufacturers - Specialty & Generic

Based in

Mumbai

Employees

1,355

Company website · Profile: Yahoo Finance

• Aarti Drugs' Baddi facility in Himachal Pradesh gets 3 US FDA Form 483 observations

  CNBC-TV18 · 6 Nov, 23:34

• Interim Dividend - Rs 2 Per Share

  Dividend · ex-date 9 February 2026

• Interim Dividend - Re 1 Per Share

  Dividend · ex-date 4 February 2025

• Buy Back

  Buyback · ex-date 5 September 2024

• Interim Dividend - Re 1 Per Share

  Dividend · ex-date 6 February 2024

• Buy Back

  Buyback · ex-date 4 August 2023

• Interim Dividend - Rs 1 Per Share

  Dividend · ex-date 8 February 2023

• Interim Dividend - Re 1 Per Share

  Dividend · ex-date 9 February 2022 · record date 10 February 2022

• Buyback

  Buyback · ex-date 30 March 2021 · record date 1 April 2021

Source: NSE. Latest first, 8 of 20.